Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 2,601–2,700 of 3,704
Novel Anti-Obesity Pharmacotherapies
Ghomraoui, F., & Srivastava, G. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.110685
Voies thérapeutiques dans l’hépatopathie stéatosique métabolique
Smati, S., Canivet, C. M., Boursier, J., & Cariou, B. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2023.03.007 · Cited by 1
Halimi, S. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2023.03.008
GLP-1-Mimetika — wegweisend zur Behandlung von Diabetes und Adipositas
Stemmer, K., & Müller, T. D. (2023) · BIOspektrum · doi:10.1007/s12268-023-1919-6
de Oliveira, J. D. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2022.tde-12042023-163803
Ajmera, V. H. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17478
Aberle, J., Lautenbach, A., Meyhöfer, S., Meyhöfer, S. M., Menzen, M., Selig, L., & Blüher, M. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01037-0
Les meilleures études en 2022 adéquates pour les soins de première ligne: De l’équipe du groupe PEER
Perry, D., Moe, S. S., Thomas, B., Lindblad, A. J., Kirkwood, J. E. M., Falk, J., Potter, J., Paige, A., & Allan, G. M. (2023) · Canadian Family Physician · doi:10.46747/cfp.6905e103
New obesity drug therapies – what is the added value?
Keller, U. B. (2022) · doi:10.36000/hbt.2022.07.002
La fretta è cattiva consigliera
Trimarchi, F. (2023) · L Endocrinologo · doi:10.1007/s40619-023-01257-y
Will Tirzepatide Become a Game-Changer Anti-Obesity Drug?
Kumar, A. (2023) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2023.01.012
Bariatric surgery the best potential treatment for nonalcoholic fatty liver disease (NAFLD)
Rangwala, B. S., Noor, T., Shakil, A., Siddiq, M. U., & Rangwala, H. S. (2023) · International Journal of Surgery Global Health · doi:10.1097/gh9.0000000000000168
McKenzie, A. L., & Athinarayanan, S. J. (2023) · medRxiv · doi:10.1101/2023.06.18.23291518
Roser, P., & Aberle, J. (2023) · CardioVasc · doi:10.1007/s15027-023-3012-y
Flekač, M. (2023) · Vnitřní lékařství · doi:10.36290/vnl.2023.051
Die neuen Wunderdrogen - eine Einordnung aus kardiologischer Sicht
Schirmer, S. H. (2023) · Info Diabetologie · doi:10.1007/s15034-023-4512-7
Diagnostic challenge: A pediatric patient with severe obesity and complications of imminent death
Srivastava, G. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100077
Traitement conservateur de l'obésité
Wimmer, R., Nagy, J., Baumgartner, A., et al. (2023) · Forum Médical Suisse ‒ Swiss Medical Forum · doi:10.4414/fms.2023.09438
Pharmacotherapeutics efficacy in obesity treatment: A systematic review
Tarboush, B. A., Karali, H. F., Zaigham, M. T., Ibrahim, G., & Farhad, E. S. (2023) · International Journal of Advanced Community Medicine · doi:10.33545/comed.2023.v6.i1a.256
The Management of Obesity in 2023: An Update
Glazer, S. A. (2023) · Canadian Primary Care Today · doi:10.58931/cpct.2023.118 · Cited by 2
Kirby, M. (2023) · Trends in Urology & Men s Health · doi:10.1002/tre.927
Small intestine is a big player!
Boškoski, I. (2023) · Digestive Endoscopy · doi:10.1111/den.14624
Association Between Weight Reduction and Employees’ Healthcare Cost
Peasah, S. K., Drnach, A. A., Rosenberg, E., & Good, C. B. (2023) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0000000000002938
MacKay, D., Rahman, T., Little, J. P., Jin, S., & BAJAJ, H. S. (2023) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2023.08.001
Davidson, M. B. (2023) · JAMA · doi:10.1001/jama.2023.9959
The energy-rush and insulin model of obesity
Jia, H. (2023) · Research Ideas and Outcomes · doi:10.3897/rio.9.e108748
Obesidad : Un breve repaso a su tratamiento
Rodríguez, J. T. (2023) · Revista de la Facultad de Medicina · doi:10.37345/23045329.v1i34.96
Effects of Replacing a Central Glycine Residue in GLP‐1 on Receptor Affinity and Signaling Profile
Brown, K. A., & Gellman, S. H. (2023) · ChemBioChem · doi:10.1002/cbic.202300504
Reproduction and Anti-Obesity Medications: A Review of Current Evidence
Saldívar-Cerón, H. I. (2023) · The Journal of Reproduction · doi:10.58779/issn.2954-467x.tjor2023.v2.n2.27 · Cited by 2
Kommentar zu „Nichtalkoholische Steatohepatitis: Besserung durch bariatrische Operation?“
Boettler, T. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2107-3141
Schirmer, M., Brandt, S., Zorn, S., & Wabitsch, M. (2023) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2079-9133 · Cited by 1
Adipositastherapie – werden Pharmakotherapien die Alternative zur metabolischen Chirurgie sein?
Müller, T. D., & Blüher, M. (2023) · Gynäkologische Endokrinologie · doi:10.1007/s10304-023-00527-0
Pharmacotherapy of Obesity: An Updated Overview
Hussein, M. T. E., & Favell, D. (2023) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2023.104750
The liver adventures of bariatric endoscopy
Boškoski, I. (2023) · Endoscopy · doi:10.1055/a-2160-1581
L’endoscopie bariatrique et métabolique. États des lieux et futur
Thobois, M., Gomercic, C., Piche, T., & Vanbiervliet, G. (2023) · Nutrition Clinique et Métabolisme · doi:10.1016/j.nupar.2023.09.001
Gut Hormones and Metabolic Syndrome
Bhat, S. Z., Park, H. K., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_25-2
Diabesity Treatments Today and Tomorrow
Pavlakis, G., & Goldman, J. D. (2023) · ADCES in Practice · doi:10.1177/2633559x231202497
Characteristics of the Latest Therapeutic Agent for Diabetes
Yun, N. (2023) · Journal of Korean Diabetes · doi:10.4093/jkd.2023.24.3.148
Müller, T. D. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2102-3927
Die Zukunft gehört den Polyagonisten
Glaser, A. (2023) · Info Diabetologie · doi:10.1007/s15034-023-4573-7
Inkretin-Agonisten: In 30 Jahren vom Geheimtipp zum Bestseller
Nauck, M. A. (2023) · Deutsches Ärzteblatt · doi:10.3238/persdia.2023.11.03.01
Liuzzo, G., & Patrono, C. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad674
Tirzepatide: A promising treatment for obesity?
Niedbala, C. G., & Sprague, R. (2023) · JAAPA · doi:10.1097/01.jaa.0000979484.51712.33
Pharmacological Strategies for Pediatric Obesity
Fox, C. K., Raatz, S. J., & Sweeney, B. R. (2023) · Springer eBooks · doi:10.1007/978-3-031-37380-0_6 · Cited by 2
Houben, J., Carpentier, Y., Paulissen, G., Snick, G. V., & Soetewey, A. (2023) · Nutrients · doi:10.3390/nu15224780 · Cited by 1
Effective Anti-Obesity Drugs Make Losing Weight a Big Deal
Williams, S. C. P. (2023) · Engineering · doi:10.1016/j.eng.2023.11.005
Ordinaries 13: apparent spite & apparent altruism
Burnham, T. C., & Phelan, J. (2023) · Journal of Bioeconomics · doi:10.1007/s10818-023-09341-x
Patient Perception of Endoscopic and Medical Therapies for Weight Loss
Saumoy, M., Gao, Y., Allison, K. C., Cronholm, P. F., Pickett‐Blakely, O., Kochman, M. L., & Thiruvengadam, N. R. (2023) · Techniques and Innovations in Gastrointestinal Endoscopy · doi:10.1016/j.tige.2023.11.001
IV CardioMIR: el Congreso de los Jóvenes Cardiólogos
Laffond, A. E., Borrego, J., Calle, D. G., & Guillén, P. L. C. (2023) · REC CardioClinics · doi:10.1016/j.rccl.2023.11.001
Lilienfeld-Toal, A. V., Tews, D., & Lilienfeld-Toal, H. V. (2023) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2185-7646
Genetische Ursachen der Adipositas und ihre therapeutischen Implikationen
Rajcsanyi, L. S., Schmidt, J., Düerkop, S., Grote, L., Peters, T., Körner, A., Fischer‐Posovszky, P., & Hinney, A. (2023) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2185-6864
Alsaab, J. S. (2023) · Pharmacology Toxicology and Biomedical Reports · doi:10.5530/ptb.2023.9.3
Novedades en los Standards of Care in Diabetes 2023
Hernández, C. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.2023.1.art1
Zorampari, C., Gupta, R., & Gupta, L. K. (2023) · European Medical Journal · doi:10.33590/emj/10306493
Hönemann, J., & Jordan, J. (2024) · Hypertension Research · doi:10.1038/s41440-023-01560-z
Retatrutide as a Novel Treatment for Obesity and Type 2 Diabetes
Mikhail, N. E. (2023) · Current Research in Diabetes & Obesity Journal · doi:10.19080/crdoj.2023.16.555949 · Cited by 2
Finer, N. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch18
La medicina cardiometabolica nell’obesità
(2024) · il Diabete · doi:10.30682/ildia2304d
Retatrutide: “tre farmaci in uno” per il trattamento dell’obesità. Uno studio di fase 2
Bufano, A., & Castagna, M. G. (2024) · L Endocrinologo · doi:10.1007/s40619-024-01421-y
General Treatment of Pediatric Obesity
Benavent, M. M. (2023) · Springer eBooks · doi:10.1007/978-3-031-26727-7_9
Severe obesity in youth: health implications and treatment strategies
van de Pas, K. G. H. (2024) · Research Publications (Maastricht University) · doi:10.26481/dis.20240301kp
Blüher, M. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01150-8
Racial and Ethnic Differences in Obesity Treatment in the Veterans Affairs Healthcare SystemPreprint
Tisdale, R. L., Beyene, T. J., Tang, W., Heidenreich, P. A., Asch, S. M., & Yong, C. M. (2024) · medRxiv · doi:10.1101/2024.02.02.24302244
Obésité : entre pléthore thérapeutique et questionnements nécessaires
Halimi, S. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.01.013 · Cited by 1
Woch, B., Bereza, D., Sokołowska, K., Kulak, M., Moreau, I., Polańska, P., & Lang, M. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.58.004 · Cited by 2
Hany, M., & Torensma, B. (2024) · Journal of Bariatric Surgery · doi:10.4103/jbs.jbs_18_23
Wahl, A. (2024) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.24.0055
Clinical Trial on and Regulatory Considerations for Herbal Medicines for Lifestyle Diseases
Bhargava, S., Dhara, A. K., Singhal, M., Sethiya, N. K., Bhavna, Shilpi, S., Rana, V. S., Dubey, A. K., Behera, A., & Nautiyal, A. (2023) · Springer eBooks · doi:10.1007/978-981-99-7703-1_29
Targeting the Natriuretic Peptide System to Improve Outcomes
Udell, J. A., & Armstrong, D. W. J. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.01.009
Luca, F. D., Velardi, V., Candido, R., & Bernardi, S. (2024) · L Endocrinologo · doi:10.1007/s40619-024-01446-3
Dow, C. T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15500-0.00007-4
Weber, M. M., Price, R., & Mack, P. F. (2024) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2024.111416
Konservative Adipositastherapie
Kretschmer, A. C., Arjune, S., & Hanßen, R. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01160-6
Neue Behandlungsmöglichkeiten der Adipositas
Heitlinger, E., & Keller, U. B. (2024) · doi:10.36000/hbt.2023.11.001
Use of Pharmacotherapy in Obesity Management
Wei, T. K. (2024) · The Singapore Family Physician · doi:10.33591/sfp.49.9.u5
b. Part II: Early Vascular Aging and Obesity Treatment
Jordan, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15512-3.00037-4
Nouveaux traitements contre l’obésité
Sarma, S., Tran, S., & Fralick, M. (2024) · Canadian Medical Association Journal · doi:10.1503/cmaj.230820-f
Obesity and Current Treatment Approaches: A Comprehensive Review
Mathialagan, K., Madhumitha, R., Muralidharan, K., & Jang, S.-J. (2024) · Journal of Translational Gastroenterology · doi:10.14218/jtg.2023.00040 · Cited by 1
(2024) · American Journal on Addictions · doi:10.1111/ajad.13528
Access to Anti-Obesity GLP-1s for Medicare-Aged AdultsPreprint
Rodriguez, P. J., Zhang, V., Gratzl, S., Cartwright, B. M. G., Do, D., Stucky, N. L., & Emanuel, E. (2024) · medRxiv · doi:10.1101/2024.03.26.24304923
Tirzepatide cardiovascular benefits and adverse events assessment: a Bayesian network meta-analysisPreprint
gong, X., cheng, P., han, Y., li, Q., Song, C., & Zhao, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-4159026/v1
Aberle, J., Lautenbach, A., Meyhöfer, S., Meyhöfer, S. M., Menzen, M., Selig, L., Mai, K., & Blüher, M. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01169-x
Recent Progression of Incretin-Based Obesity Treatment
Choi, D. (2024) · Korean Journal of Medicine · doi:10.3904/kjm.2024.99.2.78
Incretins and the metabolic syndrome
Karásek, D. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.020 · Cited by 1
Einladung zur Mitgliederversammlung
(2024) · Aktuelle Ernährungsmedizin · doi:10.1055/a-2219-1449
Tirzepatid als Alternative zur bariatrischen Chirurgie
Hubert, M. (2024) · Info Diabetologie · doi:10.1007/s15034-024-4951-9
Marinho, L. L. (2024) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2024.tde-25042024-113753
Bariatric Surgery and Brain Health: A Systematic Review and Meta-AnalysisPreprint
van Reekum, E. A., Darcy, M., Drage, J., Xu, J., Ng, K., Forestell, B., Santesso, N. A., Joundi, R. A., Wong, J. A., Doumouras, A. G., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4813679 · Cited by 1
Puchnerová, V., Jenšovský, M., Ošťádal, P., & Bonaventura, J. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.039
Lytvyak, E., Zarrinpar, A., Ore, C. L. D., Lee, E., Yazdani-Boset, K., Horgan, S., & Grunvald, E. L. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100111 · Cited by 1
Holmberg, S., Lendahls, L., & Alle, K.-Å. (2024) · PLoS ONE · doi:10.1371/journal.pone.0303021 · Cited by 1
Tirzepaptide: A Promising Option for Treating Obesity and Overweight
Amit, M. K. S. (2024) · International Journal of Science and Research (IJSR) · doi:10.21275/sr24305143919
Schiavon, C. A. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07272-8
Obesity and Muscle: Measurement methods and comorbidities
Sizoo, D. (2024) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.992833908 · Cited by 1
Lilienfeld-Toal, A. V., Tews, D., & Lilienfeld-Toal, H. V. (2024) · Aktuelle Ernährungsmedizin · doi:10.1055/a-2296-1247
Pharmacotherapy for Obesity: Recent Evolution and Implications for Cardiovascular Risk Reduction
Maki, K. C., Kirkpatrick, C. F., Allison, D. B., & Gadde, K. M. (2024) · Contemporary cardiology · doi:10.1007/978-3-031-54960-1_13
Current status of novel weight loss interventions
Tariq, N., Jacobucci, R. P., & Ali, A. B. (2024) · Journal of Investigative Medicine · doi:10.1177/10815589241241403
deLateur, B. J. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780197649176.003.0028
Bello, A. N., Sogunro, E. O., & Adeniyi, M. M. (2024) · African Journal of Management and Business Research · doi:10.62154/qa1zr059
GLP1R Agonists Activate Human POMC NeuronsPreprint
Mazzaferro, S., Chen, H. C., Cahn, O., Yang, A., Shepilov, D., Chen, J., Alcaino, C., Macarelli, V., Mali, I. D., Gribble, F. M., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4855485
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.